Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION-1 trial of RYZ101 versus standard of care in progressed SSTR-positive GEP-NET after prior 177Lu-SSA
NL-OMON59137Phase 3Active, not recruiting
- Sponsor
- RayzeBio
- Start
- Jan 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of actinium-225 dotatate in Gastroenteropancreatic Carcinoid Tumor (3 arms), sponsored by RayzeBio. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON59137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59137.